Xenetic Biosciences Expands CAR T-Cell Therapy R&D Partnership with Scripps Research

Xenetic Biosciences to Extend R&D Agreement with the Scripps Research Institute

Announcement

Xenetic Biosciences Inc., a leading biopharmaceutical company popularly known for its innovative immune-oncology technologies to identify difficult oncology indications, has extended its collaborative agreement with the Scripps Research Institute (TSRI) for elevating the development of Xenetic’s development program that evaluates the merged CAR T-cell and DNase I therapies. The expansion of research and development will polish the clinical trials to shine out the best in the healthcare market.

Xenetic’s Current Developmental Status

Xenetic’s uniform DNase I candidate, XBIO-051, is under preclinical development for compiling in CAR-T cell therapy for solid tumors and hematologic malignancies. The studies held at TSRI with the help of metastatic melanoma and lymphoma models have revealed that the integration of DNase I with CAR T-cells potentially diminishes tumor stress, reduces metastatic lesions, and doubles the chances of survival in comparison to the CAR T-cell monotherapy. Most prominently, the systematic DNase I reduces neutrophil extracellular traps (NETs), improves CAR-T cells’ efficacy by elevating the infiltration of endogenous T cells and CAR-T cells into tumors, and moderates the immunosuppressive tumor microenvironment (TME). Due to these remarkable results, the research program continued to add models of leukemia and lymphoma to secure validation for the studies.

Xenetic’s Platform Description

The xenetic’s DNase-based oncology platform is introduced to target NETs. It is a web-like structure made of extracellular chromatin with a coating of proteins and histones. In conditions like cancer, NETs are eliminated by activated neutrophils into the TME and blood, which promotes systemic and local immunosuppression and cancer circulation. The decrease in NETs stress through application of Xenetic’s proprietary recombinant human DNase I showed improvement in the efficacy of immunotherapy, chemotherapy in preclinical animal models and approved cell therapy.

Xenetic is performing consistently towards its advancement in DNase-based technology with its phase 1 clinical development for the cure of pancreatic carcinoma and metastatic solid tumors or other locally advanced tumors.

Views and Statements

Interim Chief Executive Officer and Chief Financial Officer of Xenetic, James Parslow, said, “We take the honor to announce the expansion of our collaboration with Scripps Research to discover the full-length potential of our DNase-based oncology platform. The data created to date continues to be empowering, and we believe in providing a competitive rationale for introducing DNase I as an adjunctive treatment to enhance therapeutic results in patients undergoing CAR T-cell therapy. We are thankful to the Scripps Research team, also we are looking forward to accelerating their expertise and knowledge.”